更新于：2024-11-04
Bisoprolol Fumarate
富马酸比索洛尔
更新于：2024-11-04
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C40H66N2O12 |
InChIKeyVMDFASMUILANOL-WXXKFALUSA-N |
CAS号104344-23-2 |
关联
42
项与 富马酸比索洛尔 相关的临床试验A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Bisoprolol Fumarate 5 mg Film-coated Tablets and Reference Product (Concor 5) in Healthy Thai Volunteers under Fasting Conditions
富马酸比索洛尔片（5mg）在中国健康受试者中空腹和餐后给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
富马酸比索洛尔片在健康研究参与者中的单剂量、随机、开放、交叉、两制剂、两周期空腹和餐后人体生物等效性试验
100 项与 富马酸比索洛尔 相关的临床结果
登录后查看更多信息
100 项与 富马酸比索洛尔 相关的转化医学
登录后查看更多信息
100 项与 富马酸比索洛尔 相关的专利（医药）
登录后查看更多信息
73
项与 富马酸比索洛尔 相关的文献（医药）2024-06-01PCN reports : psychiatry and clinical neurosciences
A case of reinitiation of modified electroconvulsive therapy 2 weeks after modified electroconvulsive therapy‐induced Takotsubo cardiomyopathy in a male patient with major depressive disorder
Article
作者: Sakuma, Kei ; Haruyama, Akiko ; Suzuki, Eiji ; Kezuka, Dai
Abstract:
Background:
Takotsubo cardiomyopathy (TCM) is a left ventricular dysfunction resembling acute coronary syndrome. Its prognosis is generally favorable; however, a subset of patients may present with severe complications. TCM is a rare side‐effect of modified electroconvulsive therapy (ECT); it has been reported in 22 female and two male patients. Eight cases of ECT reinitiation after TCM have been reported (all females), with the shortest duration being 3 weeks.
Case Presentation:
We report the case of a 61‐year‐old man with a history of major depressive disorder and no history of heart disease or previous ECT treatment. Antidepressants had been ineffective, and ECT was indicated. After the third ECT session, the patient complained of chest pain and shortness of breath. Electrocardiography revealed ST elevation, and catheter angiography was used to diagnose TCM. The patient had mild heart failure but remained stable. Recognizing that ECT was effective, the patient asked for it to be reinitiated. We confirmed that the cardiac function had been normalized, applied a bisoprolol fumarate patch as a preventive measure, and reinitiated ECT 14 days after the onset of TCM. ECT was performed five times, with no recurrence of TCM and a marked improvement in depression.
Conclusion:
We describe a male patient with major depressive disorder who underwent reinitiation of ECT 2 weeks after ECT‐induced TCM. Therefore, TCM should be recognized as a side‐effect of ECT, even in men. Moreover, depending on whether the patient's condition is stable, ECT can be successfully performed in patients with TCM.
2024-01-01Journal of separation science
The improvement of routine drug quality control analysis of some antihypertensive drugs using high‐performance thin‐layer chromatography densitometry method with greenness profile evaluation
Article
作者: Tohamy, Salwa I ; Abdelaleem, Eglal A ; Abdelhamid, Nessreen S ; Lashien, Adel ; Amin, Mahmoud M
The common antihypertensive drugs are B‐blockers and diuretics. For the determination of beta‐blocker medicines (bisoprolol fumarate and carvedilol) and diuretic drug (Furosemide), new and accurate chromatographic method has been developed. The separation was achieved using a developing system that includes chloroform:methanol:ethyl acetate:ammonia (6:2:2:0.2 by volume) as a mobile phase and the bands were detected at 240 nm. The concentration ranges were 5–25, 1–7, and 1–3.5 μg/band for bisoprolol fumarate, carvedilol, and furosemide, respectively. This chromatographic approach is the first methodology for simultaneously determining bisoprolol fumarate, carvedilol, and furosemide in their pure forms and in their pharmaceutical dosage forms. The advantages of using known analytical procedures are their simplicity, speed, cost effectiveness, lack of laboriousness, and ability to save time as the three tablets are determined in one step and can be used for routine analysis of the investigated combinations in quality control laboratories. According to International Conference of Harmonization guidelines, the established procedures have been validated, and the results were statistically compared to those obtained by the reported reversed‐phase–high‐performance liquid chromatography methods using Student's t‐test and F‐test, with no significant difference between them, indicating that the proposed methods can be used for routine drug quality control analysis.
2023-09-01Journal of AOAC International
Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.
Article
作者: Omran, Ahmed A ; Mohamed, Mahmoud A ; Binsaleh, Ammena Y ; Mahmoud, Osama A ; Almalki, Manal A
BACKGROUND:
Antihypertensives bisoprolol fumarate (BIS) and perindopril arginine (PER) were simultaneously determined in their pure, bulk, and combined tablet dosage form.
OBJECTIVE:
This study develops a novel, reproducible, and accurate Reversed phase high-performance liquid chromatography (RP-HPLC) and Reversed phase ultra-performance liquid chromatography (RP-UPLC) with photodiode array detection techniques, which were then applied to in vitro dissolution studies.
METHODS:
The first RP-HPLC method relied on isocratic elution using a mobile phase of methanol-0.05 M phosphate buffer pH 2.6 (1 + 1, by volume), and separation was performed using a Thermo Hypersil C8 column (150 mm × 4.6 mm, 5 μm). Ion-pair UPLC was the second method. An acceptable resolution was achieved using an RP-C18 chromatographic column, Agilent Eclipse (100 × 2.1 mm, 1.7 μm), with a mobile phase containing 0.005 M sodium 1-heptane sulfonate-triethylamine (64 + 1 + 35, by volume), adjusted with phosphoric acid to a pH of 2.0. RP-HPLC used a 1.0 mL/min flow rate, while UPLC used 0.5 mL/min, and the two methods used detection at 210 nm.
RESULTS:
Calibration curves of BIS and PER were linear for RP-HPLC and RP-UPLC methods at 0.5-15 and 0.5-40 μg/mL, respectively. BIS and PER had RP-UPLC LODs of 0.22 and 0.10 μg/mL, respectively, and LOQs of 0.68 and 0.31 μg/mL, respectively. As a result, the approach has been effectively applied to in vitro dissolution testing for drugs in generic and reference products, showing that the two products are comparable. The Six Sigma approach was implemented to compare the recommended and United States Pharmacopeia (USP) procedures, which both exhibited process capability index (Cpk) >1.33. A content uniformity test demonstrated that the drugs in their dosage form met the acceptance limit (85-115%). The degradation products were reliably distinguished from pure drugs for a range of retention times.
CONCLUSION:
In their commercial drug product, the proposed method could be used in QC laboratories for concurrent testing, content uniformity, and in vitro dissolution investigations of BIS and PER. The methods were successfully validated per International Council for Harmonisation (ICH) guidelines.
HIGHLIGHTS:
This study is innovative since it is the first to establish and validate specific and reproducible UPLC and HPLC methods for the concurrent quantitation of the studied drugs in their binary mixture and application to lean Six Sigma, content uniformity, and comparative dissolution approaches.
100 项与 富马酸比索洛尔 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 心房颤动 | 日本 | 2013-06-14 | |
| 心动过速 | 日本 | 2013-06-14 | |
| 心脏衰竭 | 日本 | 2011-05-20 | |
| 原发性高血压 | 日本 | 1990-09-28 | |
| 心绞痛 | - | 1986-01-01 | |
| 高血压 | - | 1986-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 43 | 鹽鹽積醖壓範壓糧壓艱(獵蓋鏇鬱鏇憲範淵餘鬱) = 鏇繭餘壓觸繭襯襯鑰鹹 遞鑰窪顧築觸壓餘築觸 (夢壓製鑰簾餘餘網糧鏇, 窪鹹願製顧憲選鏇顧憲 ~ 鹹積淵鏇構築構齋築網) 更多 | - | 2022-03-10 | |||
鹽鹽積醖壓範壓糧壓艱(獵蓋鏇鬱鏇憲範淵餘鬱) = 壓鏇獵醖觸壓網齋獵鏇 遞鑰窪顧築觸壓餘築觸 (夢壓製鑰簾餘餘網糧鏇, 醖憲夢鏇膚獵艱窪築鹽 ~ 構壓構淵繭製齋醖鏇遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用